SAB4300487
Anti-MET (Ab-1349) antibody produced in rabbit
affinity isolated antibody
别名:
Anti-AUTS9 antibody produced in rabbit, Anti-HGFR antibody produced in rabbit, Anti-RCCP2 antibody produced in rabbit, Anti-c-Met antibody produced in rabbit, Anti-met proto-oncogene (hepatocyte growth factor receptor) antibody produced in rabbit
生物来源
rabbit
偶联物
unconjugated
抗体形式
affinity isolated antibody
抗体产品类型
primary antibodies
克隆
polyclonal
表单
buffered aqueous solution
分子量
~156 kDa
种属反应性
mouse, rat, human
浓度
1 mg/mL
技术
western blot: 1:500-1:1000
同位素/亚型
IgG
免疫原序列
(E-H-Y-V-H)
NCBI登记号
UniProt登记号
运输
wet ice
储存温度
−20°C
靶向翻译后修饰
unmodified
基因信息
human ... MET(4233)
一般描述
MET/c-Met (mesenchymal-epithelial transition factor) is a tyrosine kinase receptor , that is located on human chromosome 7q31.
Receptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
免疫原
Peptide sequence around aa. 1347-1351 (E-H-Y-V-H), according to the protein MET.
生化/生理作用
MET/c-Met (mesenchymal-epithelial transition factor) controls several biological processes like cell scattering, survival, proliferation, migration and c-MET signaling.
特点和优势
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
外形
Solution in phosphate-buffered saline containing 0.02% sodium azide and 50% glycerol
免责声明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品？
试试我们的产品选型工具.
储存分类代码
10 - Combustible liquids
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
此项目有
The c-Met receptor: Implication for targeted therapies in colorectal cancer
Safaie Qamsari E, et al.
Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine, 39(5) (2017)
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
Baljevic M, et al.
Annals of Hematology, 96(6), 977-985 (2017)
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
Choueiri TK, et al.
Journal of Clinical Oncology, 31(2), 181-186 (2013)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持